A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
for
Relapsed Refractory Multiple Myeloma
Location: New Haven CT, Seattle WA
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07391657
Phase3, Recruiting
Active & Responsive
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
for
Relapsed/Refractory Multiple Myeloma
Location: New York NY, Hackensack NJ, Richmond VA, Durham NC,
Sponsor: Caribou Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT05722418
Phase1, Recruiting
Active & Responsive
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Location: Omaha NE, West Hollywood CA
Sponsor: Oncotherapeutics
Sex: All
Age: 0+
Code: NCT06115135
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
for
Multiple Myeloma
Location: St. John's, Halifax, Montreal, Toronto, London,
Sponsor: Canadian Myeloma Research Group
Sex: All
Age: 65+
Code: NCT05272826
Phase2, Recruiting
Active & Responsive
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Atlanta GA, Portland OR, Duarte CA, Palo Alto CA
Sponsor: Kelonia Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07075185
Phase1, Recruiting
Active & Responsive
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma